Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase

Authors: Qi Ma, Kun Zhang, Sunny Guin, Yong-Qing Zhou, Ming-Hai Wang

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Activation of the RON receptor tyrosine kinase, a member of the c-MET family, regulates tumorigenic phenotypes. The RON extracellular domains are critical in regulating these activities. The objective of this study was to determine the role of the first IPT domain in regulating RON-mediated tumorigenic activities and the underlying mechanisms.

Results

Two RON variants, RON160 and RONE5/6in with deletion and insertion in the first IPT domain, respectively, were molecularly cloned. RON160 was a splicing variant generated by deletion of 109 amino acids encoded by exons 5 and 6. In contrast, RONE5/6in was derived from a transcript with an insertion of 20 amino acids between exons 5 and 6. Both RON160 and RONE5/6in were proteolytically matured into two-chain receptor and expressed on the cell surface. RON160 was constitutively active with tyrosine phosphorylation. However, activation of RONE5/6in required ligand stimulation. Deletion resulted in the resistance of RON160 to proteolytic digestion by cell associated trypsin-like enzymes. RON160 also resisted anti-RON antibody-induced receptor internalization. These features contributed to sustained intracellular signaling cascades. On the other hand, RONE5/6in was highly susceptible to protease digestion, which led to formation of a truncated variant known as RONp110. RONE5/6in also underwent rapid internalization upon anti-RON antibody treatment, which led to signaling attenuation. Although ligand-induced activation of RONE5/6in partially caused epithelial to mesenchymal transition (EMT), it was RON160 that showed cell-transforming activities in cell focus formation and anchorage-independent growth. RON160-mediated EMT is also associated with increased motile/invasive activity.

Conclusions

Alterations in the first IPT domain in extracellular region differentially regulate RON mediated tumorigenic activities. Deletion of the first IPT results in formation of oncogenic variant RON160. Enhanced degradation and internalization with attenuated signaling cascades could be the mechanisms underlying non-tumorigenic features of RONE5/6in.
Appendix
Available only for authorised users
Literature
1.
Ronsin C, Muscatelli F, Mattei MG, Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993, 8: 1195-1202.PubMed
2.
Benvenuti S, Comoglio PM: The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol. 2007, 213: 316-325. 10.1002/jcp.21183CrossRefPubMed
3.
4.
Wang MH, Lee W, Luo YL, Weis MT, Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumorigenic phenotypes in thyroid cancer cells. J Pathol. 2007, 213: 402-411. 10.1002/path.2245CrossRefPubMed
5.
Wilson CB, Ray M, Lutz M, Sharda D, Xu J, Hankey PA: The RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity. J Immunol. 2008, 181: 2303-2310.CrossRefPubMed
6.
Chen YQ, Fisher JH, Wang MH: Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J Immunol. 1998, 161: 4950-4959.PubMed
7.
Lu Y, Yao HP, Wang MH: Multiple Variants of the RON Receptor Tyrosine Kinase: Biochemical Properties, Tumorigenic Activities, and Potential Drug Targets. Cancer Letter. 2007, 257: 157-164. 10.1016/j.canlet.2007.08.007.CrossRef
8.
Wang MH, Yao HP, Zhou YQ: Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol Sin. 2006, 27: 641-650. 10.1111/j.1745-7254.2006.00361.xCrossRefPubMed
9.
Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM: The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res. 2007, 67: 6075-6082. 10.1158/0008-5472.CAN-06-4128CrossRefPubMed
10.
Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM: The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA. 2007, 104: 7570-7575. 10.1073/pnas.0702095104PubMedCentralCrossRefPubMed
11.
Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM: Overexpression of the RON gene in human breast carcinoma. Oncogene. 1998, 16: 2927-2933. 10.1038/sj.onc.1201812CrossRefPubMed
12.
Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR: Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 2005, 11: 2222-2228. 10.1158/1078-0432.CCR-04-1761CrossRefPubMed
13.
Zhou YQ, He C, Chen YQ, Wang D, Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene. 2003, 22: 186-197. 10.1038/sj.onc.1206075CrossRefPubMed
14.
Eckerich C, Schulte A, Martens T, Zapf S, Westphal M, Lamszus K: RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. J Neurochem. 2009, 109: 969-980. 10.1111/j.1471-4159.2009.06027.xCrossRefPubMed
15.
Wang D, Shen Q, Chen YQ, Wang MH: Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene. 2004, 23: 1668-1680. 10.1038/sj.onc.1207282CrossRefPubMed
16.
Côté M, Miller AD, Liu SL: Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence. Biochem Biophys Res Commun. 2007, 360: 219-225. 10.1016/j.bbrc.2007.06.033PubMedCentralCrossRefPubMed
17.
Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009, 119: 1438-1449. 10.1172/JCI38019PubMedCentralCrossRefPubMed
18.
Xu XM, Wang D, Shen Q, Chen YQ, Wang MH: RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene. 2004, 23: 8464-8474. 10.1038/sj.onc.1207907CrossRefPubMed
19.
Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, Brattain L, Levea C, Sun FL, Keane DM, Gibson NW, Brattain MG: Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem. 2009, 284: 10912-10922. 10.1074/jbc.M809551200PubMedCentralCrossRefPubMed
20.
Guin S, Ma Q, Padhye S, Zhou YQ, Yao HP, Wang MH: Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. Cancer Chemother Pharmacol. 2010
21.
Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, Waltz SE, Lowy AM: Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res. 2010, 70: 1130-1140. 10.1158/0008-5472.CAN-09-0761PubMedCentralCrossRefPubMed
22.
Guin S, Wang MH: Down-Regulation of MET/RON Receptor Tyrosine Kinases in Colon Cancer Cells under Chronic Hypoxia as A Mechanism for Resistance towards Targeted Therapy. Proceedings of AACR 101th Annual Meeting: 7-21. 2010, 51: 442-April ; Washington, DC
23.
Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ: Potential Therapeutics Specific to c-MET/RON Receptor Tyrosine Kinases for Molecular Targeting in Cancer Therapy. Acta Pharmacol Sinica. 2010, 31: 1181-1188. 10.1038/aps.2010.106.CrossRef
24.
Ma Q, Zhang K, Yao HP, Zhou YQ, Padhye S, Wang MH: Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence. Int J Oncol. 2010, 36: 1551-1561.PubMed
25.
Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI: Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer. 2000, 29: 147-156. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.0.CO;2-NCrossRefPubMed
26.
Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, Lerman MI: The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem. 2004, 279: 3726-3732. 10.1074/jbc.M309342200CrossRefPubMed
27.
Gherardi E, Love CA, Esnouf RM, Jones EY: The sema domain. Curr Opin Struct Biol. 2004, 14: 669-678. 10.1016/j.sbi.2004.10.010CrossRefPubMed
28.
Collesi C, Santoro MM, Gaudino G, Comoglio PM: A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol. 1996, 16: 5518-5526.PubMedCentralCrossRefPubMed
29.
Zhang K, Zhou YQ, Yao HP, Wang MH: Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells. Int J Oncol. 2010, 36: 255-264.PubMed
30.
Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH: Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther. 2006, 5: 1179-1186.CrossRefPubMed
31.
Zhang K, Yao HP, Wang MH: Activation of RON Differentially Regulates Claudin Expression and Localization: Role of Claudin-1 in RON-Mediated Epithelial Cell Motility. Carcinogenesis. 2008, 29: 552-559. 10.1093/carcin/bgn003CrossRefPubMed
32.
Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH: Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res. 2000, 261: 229-238. 10.1006/excr.2000.5012CrossRefPubMed
33.
Guin S, Yao HP, Wang MH: RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity. Mol Pharm. 2010, 7: 386-797. 10.1021/mp900168vCrossRefPubMed
34.
Morris GE, Jackson PJ: Identification by protein microsequencing of a proteinase-V8-cleavage site in a folding intermediate of chick muscle creatine kinase. Biochem J. 1991, 280: 809-811.PubMedCentralCrossRefPubMed
35.
Evnin LB, Vasquez JR, Craik CS: Substrate Specificity of Trypsin Investigated by Using a Gentic Selection. Proc Natl Acad Sci USA. 1990, 87: 6659-6663. 10.1073/pnas.87.17.6659PubMedCentralCrossRefPubMed
36.
Wang MH, Julian FM, Breathnach R, Godowski PJ, Takehara T, Yoshikawa W, Hagiya M, Leonard EJ: Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain. J Biol Chem. 1997, 272: 16999-17004. 10.1074/jbc.272.27.16999CrossRefPubMed
37.
Mark MR, Lokker NA, Zioncheck TF, Luis EA, Godowski PJ: Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding. J Biol Chem. 1992, 267: 26166-26171.PubMed
38.
Komada M, Hatsuzawa K, Shibamoto S, Ito F, Nakayama K, Kitamura N: Proteolytic processing of the hepatocyte growth factor/scatter factor receptor by furin. FEBS Lett. 1993, 328: 25-29. 10.1016/0014-5793(93)80958-WCrossRefPubMed
39.
Li ZZ, Yao HP, Guin S, Padhye SS, Zhou YQ, Wang MH: Monoclonal antibodies-induced down-regualtion of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. Int J Oncol. 2010, 37: 473-482.PubMed
40.
Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, Comoglio PM, Giordano S: Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA. 2006, 103: 5090-5095. 10.1073/pnas.0508156103PubMedCentralCrossRefPubMed
41.
Monticone M, Biollo E, Fabiano A, Fabbi M, Daga A, Romeo F, Maffei M, Melotti A, Giaretti W, Corte G, Castagnola P: z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response. Mol Cancer Res. 2009, 7: 1822-1834. 10.1158/1541-7786.MCR-09-0225CrossRefPubMed
42.
Santoro MM, Collesi C, Grisendi S, Gaudino G, Comoglio PM: Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol. 1996, 16: 7072-7083.PubMedCentralCrossRefPubMed
43.
Bork P, Doerks T, Springer TA, Snel B: Domains in plexins: links to integrins and transcription factors. Trends Biochem Sci. 1999, 24: 261-263. 10.1016/S0968-0004(99)01416-4CrossRefPubMed
44.
Siponen MI, Wisniewska M, Lehtio L, Johansson I, Svensson L, Raszewski G, Nilsson L, Sigvardsson M, Berglund H: Structural determination of functional domains in Early B-cell Factor (EBF) family of transcription factors reveals similarities to rel DNA binding proteins and a novel dimerisation motif. J Biol Chem. 2010, 285: 25875-25879. 10.1074/jbc.C110.150482PubMedCentralCrossRefPubMed
45.
Basilico C, Arnesano A, Galluzzo M, Comoglio PM, Michieli P: A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem. 2008, 283: 21267-21277. 10.1074/jbc.M800727200PubMedCentralCrossRefPubMed
46.
Wortinger M, Liu L: RON splice variant prevalence in human tumors. Proceedings of AACR 99th Annual Meeting: 12-16. 2008, 49: 3610-April ; San Diego, CA
47.
Robinson CJ, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001, 114: 853-865.PubMed
48.
Tacconelli A, Farina AR, Cappabianca L, Gulino A, Mackay AR: Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. Future Oncol. 2005, 1: 689-698. 10.2217/14796694.1.5.689CrossRefPubMed
49.
Merlin S, Pietronave S, Locarno D, Valente G, Follenzi A, Prat M: Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. Cancer Sci. 2009, 100: 633-638. 10.1111/j.1349-7006.2008.01079.xCrossRefPubMed
50.
Penengo L, Rubin C, Yarden Y, Gaudino G: c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene. 2003, 22: 3669-3679. 10.1038/sj.onc.1206585CrossRefPubMed
Metadata
Title
Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase
Authors
Qi Ma
Kun Zhang
Sunny Guin
Yong-Qing Zhou
Ming-Hai Wang
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-307

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Autotaxin expression and its connection with the TNF-alpha-NF-κB axis in human hepatocellular carcinoma

Research

Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations

Research

Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia

Research

An essential role for Ran GTPase in epithelial ovarian cancer cell survival

Research

Oral cancer overexpressed 1 (ORAOV1) regulates cell cycle and apoptosis in cervical cancer HeLa cells

Short communication

The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits